Latest News | Lupin Signs Pact to Acquire Rights to 9 Products from Brazilian Firm
Get latest articles and stories on Latest News at LatestLY. Drug firm Lupin on Monday said its Brazil-based unit has inked a pact to acquire rights nine products from a subsidiary of Bausch Health Companies Inc.
New Delhi, Nov 28 (PTI) Drug firm Lupin on Monday said its Brazil-based unit has inked a pact to acquire rights nine products from a subsidiary of Bausch Health Companies Inc.
The company's wholly-owned subsidiary in Brazil, MedQuimica Industria Farmaceutica, has signed a definitive agreement to acquire all rights to nine medicines from BL Industria Otica Ltda, Lupin said in a statement.
As part of the transaction, MedQuimica will acquire rights to products, including Limbitrol, Melleril and Dalmadorm, for central nervous system related conditions, it added.
Besides, it will have Bacrocin, Glyquin, Solaquin, Oxipelle and Efurix as topical oncological treatments, and Cuprimine for the treatment of Wilson's disease, the Mumbai-based drug maker said.
Also Read | India International Trade Fair 2022: Khadi India Pavilion Registers Record Sale of Rs 12.06 Crore.
"The acquired brands are well established and recognised among doctors and other members of the medical fraternity in Brazil for their reliability, safety, and trustworthiness,” MedQuimica Managing Director stated.
This transaction enhances the company's product portfolio in Brazil and also strengthens its position in the prescription market, he added.
Lupin shares rose by 1.98 per cent to close at Rs 733.70 on BSE.
(The above story is verified and authored by Press Trust of India (PTI) staff. PTI, India’s premier news agency, employs more than 400 journalists and 500 stringers to cover almost every district and small town in India.. The views appearing in the above post do not reflect the opinions of LatestLY)